CA2086094A1 - Compositions de vaccin renfermant des liposomes - Google Patents

Compositions de vaccin renfermant des liposomes

Info

Publication number
CA2086094A1
CA2086094A1 CA2086094A CA2086094A CA2086094A1 CA 2086094 A1 CA2086094 A1 CA 2086094A1 CA 2086094 A CA2086094 A CA 2086094A CA 2086094 A CA2086094 A CA 2086094A CA 2086094 A1 CA2086094 A1 CA 2086094A1
Authority
CA
Canada
Prior art keywords
compositions containing
vaccine compositions
containing liposomes
liposome
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2086094A
Other languages
English (en)
Other versions
CA2086094C (fr
Inventor
Gail L. Barchfeld
Gary Ott
Gary A. Van Nest
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2086094A1 publication Critical patent/CA2086094A1/fr
Application granted granted Critical
Publication of CA2086094C publication Critical patent/CA2086094C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composition de vaccin, comprenant une substance antigénique en association avec un liposome et une émulsion huile-dans-l'eau composée d'un peptide muramyle, d'une huile métabolisable, et éventuellement d'un agent émulsifiant supplémentaire. Les deux composants de l'adjuvant (c'est-à-dire le composant liposome/antigène et le composant émulsion) interagissent et produisent des niveaux de réponse immunitaire élevés.
CA002086094A 1990-06-29 1991-06-25 Compositions de vaccin renfermant des liposomes Expired - Fee Related CA2086094C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54658590A 1990-06-29 1990-06-29
US07/546,585 1990-06-29
PCT/US1991/004532 WO1992000081A1 (fr) 1990-06-29 1991-06-25 Compositions de vaccins contenant des liposomes

Publications (2)

Publication Number Publication Date
CA2086094A1 true CA2086094A1 (fr) 1991-12-30
CA2086094C CA2086094C (fr) 2000-05-30

Family

ID=24181076

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002086094A Expired - Fee Related CA2086094C (fr) 1990-06-29 1991-06-25 Compositions de vaccin renfermant des liposomes

Country Status (17)

Country Link
EP (1) EP0489153B1 (fr)
JP (1) JP2502234B2 (fr)
AT (1) ATE185486T1 (fr)
AU (1) AU654824B2 (fr)
BR (1) BR9106604A (fr)
CA (1) CA2086094C (fr)
DE (1) DE69131709T2 (fr)
DK (1) DK0489153T3 (fr)
ES (1) ES2138588T3 (fr)
FI (1) FI925835A0 (fr)
GR (1) GR3031528T3 (fr)
HU (1) HU220136B (fr)
IE (1) IE912286A1 (fr)
NO (1) NO924858L (fr)
OA (1) OA09800A (fr)
PT (1) PT98156B (fr)
WO (1) WO1992000081A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925142B2 (en) 2005-10-07 2018-03-27 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment
US10105435B2 (en) 2011-10-06 2018-10-23 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof
US10232052B2 (en) 2007-09-27 2019-03-19 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US11717563B2 (en) 2008-06-05 2023-08-08 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692149B1 (fr) * 1992-06-12 1995-06-09 Vacsyn France Sa Composition adjuvante de l'immunite humorale et a mediation cellulaire n'induisant pas de reponse vis-a-vis de determinants auto-antigeniques.
EP0669941A1 (fr) * 1992-11-02 1995-09-06 NICOLAU, Yves Claude Procede de reduction de la resistance a plusieurs medicaments dans des cellules et des tissus
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
AU5543294A (en) * 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DK0721505T4 (da) * 1994-07-29 2006-08-14 Innogenetics Nv Rensede hepatitis C-virus-kappeproteiner til diagnostisk og terapeutisk anvendelse
US5820880A (en) * 1995-06-07 1998-10-13 The United States Of America As Represented By The Secretary Of The Army Liposomal formulation
WO1996040243A1 (fr) * 1995-06-07 1996-12-19 U.S. Department Of The Army Liposomes contenant une glycoproteide du virus de l'immunodeficience humaine et leurs procedes d'utilisation
US7393630B2 (en) 1997-12-16 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Use of microparticles combined with submicron oil-in-water emulsions
CA2314934C (fr) 1997-12-16 2006-08-29 Chiron Corporation Utilisation de microparticules combinees avec des emulsions huile-dans-eau submicroniques
WO2000050006A2 (fr) * 1999-02-26 2000-08-31 Chiron Corporation Microemulsions a macromolecules et microparticules adsorbees
AU2002214861B2 (en) 2000-11-07 2006-09-28 Immunovaccine Technologies Inc. Vaccines with enhanced immune response and methods for their preparation
CA2453441C (fr) * 2001-07-13 2011-10-18 Nanocarrier Co., Ltd. Composition de lyophilisation de micelle polymere d'encapsulation de medicaments et procede de preparation associe
KR20030097099A (ko) * 2002-06-19 2003-12-31 현대자동차주식회사 저압 주조를 위한 금형의 용탕 충진 속도 측정장치
US8034378B2 (en) * 2002-12-27 2011-10-11 Novartis Vaccines And Diagnostics, Inc Immunogenic compositions containing phospholipid
DK2471518T3 (en) * 2009-05-18 2017-12-04 Sigmoid Pharma Ltd COMPOSITION INCLUDING OIL DROPS
AU2010270722B2 (en) 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
WO2011005772A1 (fr) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Procédés pour préparer des vésicules et formulations produites à partir de ces procédés
WO2012006367A2 (fr) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions et méthodes pour traiter la grippe
WO2012097346A1 (fr) 2011-01-13 2012-07-19 Variation Biotechnologies, Inc. Compositions et méthodes de traitement d'infections virales
EP2802353A4 (fr) 2012-01-12 2015-12-02 Variation Biotechnologies Inc Compositions et méthodes de traitement d'infections virales
RU2698906C2 (ru) 2012-01-27 2019-09-02 Вэриэйшн Биотекнолоджиз, Инк. Способы и композиции для терапевтических агентов

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199565A (en) * 1979-03-26 1980-04-22 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
HU184141B (en) * 1979-12-27 1984-07-30 Human Oltoanyagtermelo Adjuvant particles compositions containing said particles and biologically active substances adsorbed thereon and a process for the preparation thereof
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
JPS6137738A (ja) * 1984-07-31 1986-02-22 Tetsuo Nakamura Ｂ型肝炎ワクチン

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925142B2 (en) 2005-10-07 2018-03-27 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment
US10232052B2 (en) 2007-09-27 2019-03-19 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US11235069B2 (en) 2007-09-27 2022-02-01 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US11717563B2 (en) 2008-06-05 2023-08-08 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
US10105435B2 (en) 2011-10-06 2018-10-23 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof
US11077184B2 (en) 2011-10-06 2021-08-03 Immunovaccine Technologies Inc. Liposome compositions comprising PAM2Cys or PAM3Cys adjuvant and methods for inducing a humoral immune response

Also Published As

Publication number Publication date
DK0489153T3 (da) 2000-01-24
AU8323091A (en) 1992-01-23
CA2086094C (fr) 2000-05-30
JP2502234B2 (ja) 1996-05-29
EP0489153A4 (en) 1993-04-21
BR9106604A (pt) 1993-06-22
OA09800A (en) 1994-04-15
PT98156B (pt) 1998-12-31
AU654824B2 (en) 1994-11-24
HU220136B (hu) 2001-11-28
EP0489153B1 (fr) 1999-10-13
FI925835A (fi) 1992-12-22
DE69131709D1 (de) 1999-11-18
FI925835A0 (fi) 1992-12-22
HU9204136D0 (en) 1993-11-29
NO924858L (no) 1993-02-25
JPH06504759A (ja) 1994-06-02
WO1992000081A1 (fr) 1992-01-09
PT98156A (pt) 1992-04-30
ES2138588T3 (es) 2000-01-16
EP0489153A1 (fr) 1992-06-10
NO924858D0 (no) 1992-12-15
ATE185486T1 (de) 1999-10-15
GR3031528T3 (en) 2000-01-31
DE69131709T2 (de) 2000-05-25
HUT67055A (en) 1995-01-30
IE912286A1 (en) 1992-01-01

Similar Documents

Publication Publication Date Title
CA2086094A1 (fr) Compositions de vaccin renfermant des liposomes
HU905459D0 (en) Adjuvant preparation containing submicronal oil-drop emulsion
MY134811A (en) A vaccine composition comprising an antigen, a saponin and a sterol
GEP20012556B (en) Composition for Induction of Cytotoxic T- Lymphocyte Responses
LU91486I2 (fr) Emulsion huile-dans-eau comprenant du squalène, duDL-a-tocophérol et du polysorbate 80
CA2132547A1 (fr) Vaccins renfermant des vesicules d'agents tensioactifs non ioniques
AU7176087A (en) Vaccine formulation
AP9400683A0 (en) Vaccines.
CA2008856A1 (fr) Tocols employes comme adjuvant des vaccins
MX9803290A (es) Composiciones de la vacuna influenza.
CA2183435A1 (fr) Vaccins contenant des vesicules lipidiques paucilamellaires comme adjuvants immunologiques
WO2001072277A3 (fr) Methodes et compositions immunotherapeutiques
AU2458888A (en) Vaccine adjuvant
MX9603547A (es) Vacunas que contienen vesiculas de lipido paucilamelar como adyuvantes inmunologicos.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed